Chris Seiter
Our team

Chris Seiter

Chief Corporate Finance Officer

Chris provides structuring and transactional leadership for new ventures originated at RTW as well as royalty and alternative investments. Chris also provides oversight and support to the financial operations and business development of the newly formed ventures.

Prior to joining RTW, Chris served as Chief Financial Officer of two development stage biopharmaceutical companies, Trevi Therapeutics and Millendo Therapeutics. Before shifting to an operational role, Chris served as Managing Director and Head of Life Sciences Investment Banking at Bank of America Merrill Lynch where he focused on advising life sciences companies on transactions ranging from equity and debt financings to mergers and acquisitions. Chris served in the Navy as a Nuclear Submarine Officer for five years before beginning his investment banking career.

We are living in a period of unprecedented scientific discovery and RTW is at the forefront. It is invigorating to work with a group of talented and dedicated professionals that share a common goal of harnessing the power of science to improve the lives of patients.

Chris received a BA in economics cum laude from the University of Rochester and completed a graduate level program in nuclear engineering at the U.S. Naval Nuclear Power School.